Although the term implies glomerular inflammation, numerous non-inflammatory diseases can also compromise glomerular integrity. Among these, diabetic nephropathy is particularly important, as are the hereditary nephropathies, including Alport's syndrome. Registry data focus on the causes of end-stage renal disease (ESRD), so accurate data on prevalence of GN are scarce as only a relatively small number progress to dialysis or transplantation.
GN is separated into primary, when restricted to the kidney, or secondary, when the kidneys become involved in a multisystem disorder.
GN is principally classified according to histological appearance. This is not ideal, as any one biopsy pattern can result from several underlying aetiologies and many kidney insults can generate an array of histological appearances. Histology is thus best viewed as a description that is incomplete without careful clinical correlation (see box).
|Histological descriptions of GN
|Proliferative or not?||An increase in cell number; eg IgA nephropathy features an increase in mesangial cells.|
|Focal or diffuse?||Focal lesions affect <50 per cent of the sampled glomeruli. Diffuse lesions involve >50 per cent.|
|Segmental or global?||Segmental lesions affect part, while global lesions involve most, of a glomerulus.|
|Crescentic or not?||Epithelial proliferation in response to local inflammation, with fibrin deposition and adhesions filling Bowman's space.|
|Matrix or membrane?||Matrix expansion produced by mesangial cells or increase in capillary wall thickness as found with immune deposits.|
|Necrosis or sclerosis? sible scarring.||Necrosis refers to fresh cell death, while
sclerosis reflects irreversible scarring.
|Pattern, distribution and nature of immune deposits as determined by immunostaining and electron microscopy may aid diagnosis.|
For example, focal and segmental glomerulosclerosis (FSGS) affects some glomeruli but not all, and only part of any affected tuft. The disease leads to scarring. Diffuse proliferative crescentic glomerulonephritis affects most glomeruli, with increased cell number and crescent formation in Bowman's space (see image).
Diffuse proliferative crescentic glomerulonephritis
Many glomerular diseases result from immune dysregulation, either autoimmunity or an ineffective response to a foreign antigen. Antigens may be native to the glomerulus itself (as in anti-glomerular basement membrane disease), or part of trapped circulating immune complexes that cause glomerular injury through activation of complement and recruitment of inflammatory cells. An inflamed glomerulus may heal to normality, or scar with glomerulosclerosis. Associated tubulointerstitial inflammation often resolves with fibrosis. This will manifest as impaired kidney function and chronic kidney disease (CKD).
Many causes of the nephrotic syndrome are now thought to be secondary to podocyte malfunction or injury. These highly specialised cells form a crucial component of the glomerular filtration barrier.
Genetic associations of GN have been studied, but none is very specific or compelling.
Section 2: Making the diagnosis
While proteinuria is the principle hallmark of glomerular disease, clinical presentation ranges from asymptomatic urinary abnormalities through to fulminant life-threatening acute kidney injury.
Early referral for evaluation is important, as timely treatment may slow or prevent development of associated CKD.
While the likelihood of a particular GN might be determined from the age of the patient, clinical scenario and laboratory tests, diagnosis ultimately requires histological confirmation via a kidney biopsy. However, despite the appeal of a definitive tissue diagnosis, the risks of a biopsy must always be weighed against benefits. Although the complication rate is low, the findings, especially in patients with mild disease, may be of limited prognostic value.
When GN presents late, with advanced CKD and small kidneys on imaging, a biopsy is less likely to be informative - and is much more hazardous. A biopsy is therefore reserved for those patients in whom specific treatment is potentially indicated, or when assessment of prognosis is imperative.
An exception is minimal change disease in children, where the clinical presentation is so characteristic that it usually prompts a trial of corticosteroids without histological confirmation.
In very general terms, mild haematuria and low level proteinuria (particularly <1g/day) in the absence of renal impairment or hypertension are associated with a favourable long-term prognosis. Such patients are usually best managed with regular monitoring.
|Clinical presentations of glomerular disease|
|Asymptomatic urinary abnormalities||
Proteinuria usually <3g/24 hours
|Macroscopic haematuria||Typically coincides with intercurrent infection. 'Smoky' urine. Rarely clots. Requires urological investigation.||
|Abrupt onset of haematuria (usually microscopic with red cell casts), moderate proteinuria and impaired kidney function. Salt and water retention causes hypertension and oedema.||
Other post-infectious diseases such as endocarditis or an abscess
Systemic lupus erythematosus (SLE)
|The nephrotic syndrome||
Heavy proteinuria (usually >3.5g/24h) associated with hypoalbuminaemia and oedema.
Minimal change disease
|Acute kidney injury||
Rapidly progressive GN, often with clinical manifestations beyond the kidney.
Reduced glomerular filtration rate (GFR)
Small, shrunken kidneys on imaging
||Suspect GN if abnormal urinalysis
Section 3: Managing the condition
The treatment of glomerulonephritis has several objectives: to control symptomatic nephrotic syndrome when present, to slow deterioration in kidney function and, where possible, to control an underlying disease process.
Measures include treatment of BP, reduction in urinary protein excretion, control of oedema, avoidance of nephrotoxins and correction of any other consequences of the condition, including those of a reduced GFR, such as anaemia and secondary hyperparathyroidism.
Hypertension is almost ubiquitous in GN and is the key modifiable factor for preservation of kidney function. The target BP is not firmly established, but <125/75mmHg is generally advocated for those patients with >1g daily protein excretion (urine protein to creatinine ratio [uPCR] >100mg/mmol or urine albumin to creatinine ratio [uACR] >70mg/mmol).
There are convincing arguments for the use of ACE inhibitors or ARBs as first-line drugs because their renoprotective effect extends beyond their antihypertensive action. However, as salt and water overload is often present, diuretics (along with modest dietary sodium restriction) also form an important part of treatment.
In addition, lifestyle modification - weight reduction, regular exercise and smoking cessation - should be encouraged.
Proteinuria represents another important therapeutic target. There is good evidence that proteinuric urine may be toxic to the renal tubulointerstitium, so if possible it should be reduced to <0.5g/day (uPCR <50mg/mmol or uACR <35mg/mmol). There is probably little difference between using an ACE inhibitor or ARB treatment.
Whether ACE inhibitors and ARBs have an additive antiproteinuric effect remains unproven. Whilst a meta-analysis found a significantly greater reduction in proteinuria in combination (18 to 25 per cent), the study that most strongly suggested a reduction in disease progression (COOPERATE) was subsequently retracted. That said, many clinicians advocate their combined use, although the increased incidence of adverse effects mandates close supervision. Treatment of hyperlipidaemia should follow general population guidelines. Nephrotoxins, especially NSAIDs and radiocontrast agents, should be avoided where possible.
Specific treatments for individual glomerular diseases are beyond the scope of this article. However, treatment may involve measures to remove a foreign antigen, such as antibiotics for endocarditis. Otherwise, therapy generally consists of immunosuppressive strategies aimed at aberrant immune responses.
Lack of data
There is a disappointing lack of data from RCTs to assist clinical decision making, even for the more common types of GN, such as IgA nephropathy. Judgments regarding treatment must always be individualised, weighing benefits against risks.
In general, there has been little success for immune suppression in slow progressive forms of GN. The mainstays of treatment remain corticosteroids, azathioprine and cyclophosphamide. Newer agents, often developed in transplant or oncology fields, include tacrolimus, mycophenolate and rituximab.
Section 4: Prognosis and follow-up
Long-term follow-up is essential. In many cases this could be in primary care, with six to 12-monthly measurement of BP, eGFR and urinary protein excretion. Changes in any parameter should prompt a more thorough re-evaluation.
The presence of CKD and its complications requires more regular follow-up.
The natural history of the various types of GN varies greatly and is one reason histological information is so desirable.
Some forms are self-limiting. For example, <1 per cent of children with post-streptococcal GN develop CKD. For others, such as membranous GN, the prognosis is dependent on response to treatment.
Many glomerulonephritides have a range of potential outcomes depending on clinical presentation and initial biopsy appearance. For example, for IgA nephropathy presenting with recurrent macroscopic or isolated microscopic haematuria, the prognosis is excellent; for a nephritic presentation with crescentic change on biopsy, it is considerably worse. In many cases, urinary abnormalities will be present lifelong. However, an escalation in proteinuria is generally associated with a poorer prognosis. If kidney scarring is present, then progressive deterioration in function may also occur through non-immune pathways, leading to advanced CKD with an eventual need for dialysis or transplantation.
Furthermore, many forms of GN can recur in a transplant, with varying degrees of prognostic significance.
Section 5: Case Study
A 46-year-old woman was referred for assessment of proteinuria (uACR 310mg/mmol). Her medical history included hypertension in her first pregnancy and pre-eclampsia in her second. She has previously been told that she has blood in her urine, but tests have always been clear of infection. She smoked 15 cigarettes a day and had a BMI of 32. Clinical examination was unremarkable, besides a BP of 162/96 mmHg on the day. Urinalysis showed 2+ blood and 3+ protein.
Investigations revealed an eGFR of 32ml/min. Urine cytology reveals dysmorphic red blood cells. Urine culture was sterile.
Her remaining blood tests, including serum and protein electrophoresis and antinuclear antibody were normal. An ultrasound shows 10.5 cm unobstructed kidneys bilaterally.
It is likely she has had an active glomerular lesion for several years and this may have predisposed her to problems in pregnancy. It would explain persistent microscopic haematuria, although separate urological evaluation would be desirable, particularly as she smokes.
The patient was commenced on an ACE inhibitor for both her hypertension and proteinuria. A diagnostic and prognostic kidney biopsy revealed a mesangial proliferative glomerulonephritis with positive immunostaining for IgA, indicating IgA nephropathy. There was also marked hypertension-induced arteriosclerosis, as well as the significant glomerular sclerosis and 40 per cent interstitial fibrosis.
The patient was given specific education regarding IgA nephropathy as well as more generally regarding CKD. She was referred for smoking cessation counselling and given lifestyle advice.
Target BP was achieved with the addition of an ARB and a diuretic. Her uACR reduced progressively to 80mg/mmol. Her eGFR stabilised at approximately 25ml/min. However, given her age and scarring evident on the biopsy, it is likely she will progress to ESRD.
She was counselled on this matter and several potential live kidney donors came forward in the subsequent year.
Section 6: Evidence base
While there has been a paucity of clinical studies, there have been many recent publications addressing the underlying mechanisms of glomerular disease.
- Beck L Jr, Bonegio R, Lambeau G, et al: M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 2: 361(1): 11-21.
The nature of the autoimmune responses responsible for membranous GN is being uncovered rapidly - this will hopefully lead to real progress in the diagnosis, prognosis and treatment of the clinical disease.
- Donadio J Jr, Grande J, Bergstralh E, et al. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. J Am Soc Nephrol 1999; 10(8): 1772-7.
Having previously reported that dietary fish oil supplementation retarded the progression of renal disease in patients with IgA nephropathy in a two-year clinical trial, this study concluded the influence of treatment extended further.
This study is one of the few randomised trials addressing the treatment of a common GN. However, the role of fish oil, which may act by anti-inflammatory mechanisms, remains unclear. Other trials have reported conflicting results and compliance with treatment is poor.
- Sarnak M, Greene T, Wang X, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease study. Ann Intern Med 2005; 142(5): 342-51.
The MDRD trial patient cohort has been a valuable resource within nephrology and the basis for several important publications. It suggested both the rate of progression and the effectiveness of antihypertensive therapy might be related to protein excretion, itself a function of the severity of glomerular injury.
- National Collaborating Centre for Chronic Conditions. Chronic kidney disease: national clinical guideline for early identification and management in adults in primary and secondary care. Royal College of Physicians, London, 2008.
The key messages are summarised in useful algorithms on pages 19-21.
- Kidney Disease: Improving Global Outcomes (KDIGO) Clinical practice guideline on glomerulonephritis www.kdigo.org/docs/KDIGO_GN_ScopeOfWork_04-02-09.doc
KDIGO is a global, non-profit foundation aiming to improve the care and outcomes in kidney disease. It is producing a series of guidelines with the goal of identifying and harmonising current best practice. A guideline concerning GN is expected in 2011. This is likely to be a major international resource in this area.
Steddon S, Ashman N, Chesser A, Cunningham J. Oxford Handbook of Nephrology and Hypertension. Oxford University Press, Oxford, 2006.
Edinburgh Renal Unit: www.edren.org/pages/edreninfo/glomerulonephritis.php
A helpful resource for patients and healthcare professionals alike.
Atlas of Renal Pathology: www2.us.elsevierhealth.com/ajkd/atlas/
A free online atlas of renal histopathology.
A useful summary with multiple additional links out.
|CPD IMPACT: earn more credits|
These further action points allow you to earn more credits by increasing the time spent and the impact achieved.
1. Boulware L, Troll M, Jaar B, et al. Identification and referral of patients with progressive CKD: a national study. Am J Kidney Dis 2006; 48: 192.1
2. Maschio G, Alberti D, Janin G, et al: Effect of the angiotensin-converting-enzyme inhibitor, benazepril, on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-45.
3. Goto M, Wakai K, Kawamura T, et al. A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. Nephrol Dial Transplant 2009; 24(10): 3068-74.
4. Kunz R, Friedrich C, Wolbers M, et al Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148(1): 30-48.
5. Remuzzi G, Chiurchiu C, Ruggenenti P. Proteinuria predicting outcome in renal disease: nondiabetic nephropathies (REIN). Kidney Int Supp 2004; (92): S90-6.